Fig 1.
NSCLC, non-small cell lung cancer; pTest+, proportion of test positives; pTest-, proportion of test negatives; pUnknown, proportion of unknown tests. Note: pTest+ = pTP + pFP [pTP = prevalence × sensitivity × (1-pUnknown), pFP = (1-prevalence) × (1-specificity) × (1-pUnknown)]; Test- = pTN + pFN [pTN = (1-prevalence) × specificity × (1-pUnknown), pFN = prevalence × (1-sensitivity) × (1-pUnknown)]. ※ pTP, pFP, pTN, and pFN is the proportion of true positive, false positive, true negative, and false positive results, respectively. Prevalence is the percentage of patients harboring EGFR mutations in stage 3b and 4 lung adenocarcinoma.
Table 1.
Input parameters.
Table 2.
Results of cost-effectiveness in the base case and sensitivity analyses.
Fig 2.
Tornado diagram of one-way sensitivity analysis.
* Prevalence of EGFR mutation. cERT, medical cost of erlotinib; cCPEM, medical cost of cisplatin plus pemetrexed; cDOX, medical cost of docetaxel; cTest, cost of genetic test; cBSC, medical cost of best supportive care in terminal cancer patients; pUnknown, proportion of unknown tests.